AIM
EPZM

Acrospire Investment Management’s Epizyme, Inc EPZM Stock Holding History

Acrospire Investment Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100
Closed -$1K – 2228
2016
Q2 		$1K Buy
+100
New +$1.11K ﹤0.01% 1976

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Acrospire Investment Management's EPZM Position: Q3 2016 in Review

Acrospire Investment Management sold out of Epizyme, Inc (EPZM) in Q3 2016, closing a stake of 100 shares — an estimated $1K sold.

Acrospire Investment Management first reported a position in EPZM in Q2 2016 and held it in 1 quarter. The position peaked at $1K in Q2 2016. 97 funds tracked by Wall St. Rank hold EPZM as of Q3 2016.

  • Acrospire Investment Management reported no remaining Epizyme, Inc position as of Q3 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 100 Epizyme, Inc shares in Q3 2016, an estimated $1K.
  • Acrospire Investment Management first reported a position in Epizyme, Inc in Q2 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Epizyme, Inc position peaked at $1K in Q2 2016.
  • 97 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2016.

Based on Acrospire Investment Management's 13F filing for Q3 2016, filed 10 Nov 2016.